February 7, 2014
Turning the Tide: Staging
Improvements in liver monitoring continue to lag behind. Cox pointed out that a number of less-invasive blood tests -- FibroTest, SHASTA, FIB-4, Forns and APRI, for instance -- have been shown to have some value. "In this very inexpensive test, the AST to platelet ratio index is actually pretty good at predicting liver disease when compared to liver biopsy -- which again, isn't perfect," Cox said.
A newer, more advanced, completely non-invasive method -- transient elastography (a.k.a. FibroScan), approved in the U.S. in 2013 -- appears quite useful for picking up high-level liver disease and relatively useful for spotting lower-level disease, Cox said. However, the test -- which gauges liver stiffness by passing ultrasound waves through the organ -- is less effective the more overweight a patient is, and with an average price tag in the $120,000 range, Cox suggested that the technology remained an option that many facilities were unable to afford.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|What's Hot in HIV Treatment|
|Coverage of ICAAC 2014: The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy|
|A "Bad Year" for HIV Cure Research? Experts Mix Realism and Hope|
|Preventing and Treating HIV-Associated Bone Disease|
|Factors Associated With 10 Years of Continuous Viral Load Suppression on HIV Treatment|
|Challenges to Stem Cell Transplantation in HIV-Positive Patients|